Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 1a/1b Study Investigating the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Preliminary Antitumor Activity of the CDK4 Inhibitor BGB-43395, Alone or as Part of Combination Therapies in Patients With Metastatic HR+/HER2- Breast Cancer and Other Advanced Solid Tumors

NCT06120283 is registered in ClinicalTrials.gov with BeOne Medicines as lead sponsor.

NCT NCT06120283
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06120283 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 1a/1b Study Investigating the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Preliminary Antitumor Activity of the CDK4 Inhibitor BGB-43395, Alone or as Part of Combination Therapies in Patients With Metastatic HR+/HER2- Breast Cancer and Other Advanced Solid Tumors
Lead sponsor
BeOne Medicines
Phase
Phase 1
Overall status
Recruiting
Start date
December 1, 2023
Completion date
December 31, 2029
Enrollment
433 (estimated)
Sites
61

Conditions

As the registry lists them; a condition with its own page is linked.

advanced breast cancer, advanced solid tumor, her2-negative breast cancer, hormone receptor positive breast carcinoma, hormone receptor positive her-2 negative breast cancer, hormone receptor positive malignant neoplasm of breast, hormone-receptor-positive breast cancer, metastatic breast cancer